Role of matrix metalloproteinases in the pathogenesis of cardiovascular diseases;Bedeutung von matrix metalloproteinasen bei kardiovaskularen erkrankungen

Zeitschrift fur Kardiologie

Volumn 89, Issue 10, 2000, Pages 949-957

  Lamparter, S ^a   Maisch, B ^a  

^a Intensiv und Schlafmedizin   (Germany)

Author keywords

Collagen; Matrix metalloproteinase; MMP inhibitors; Tissue remodeling

Indexed keywords

COLLAGENASE INHIBITOR; MATRIX METALLOPROTEINASE;

ARTICLE; CARDIOVASCULAR DISEASE; COLLAGEN SYNTHESIS; ENZYME DEGRADATION; ENZYME RELEASE; HUMAN; HUMAN TISSUE; MEMBRANE BINDING; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN SECRETION; UNSTABLE ANGINA PECTORIS;

ANIMALS; CARDIOVASCULAR DISEASES; COLLAGEN; HUMANS; MATRIX METALLOPROTEINASES; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM;

EID: 0033765203     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920070169     Document Type: Article

References (109)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
3. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production
4. Pathogenesis of acquired aneurysms of the abdominal aorta
5. The many forms and functions of cellular proteinases
6. Intracellular degradation of newly synthesized collagen
7. Fibroblasts degrade newly synthesized collagen within the cell before secretion
8. Matrix metalloproteinases: A review
9. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease
10. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy
11. Hormonal regulation of cardiac fibroblast function
12. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αVβ3
13. Identification of 92-kDa gelatinase in human coronary atherosclerotic lesions
14. Synthetic inhibitors of matrix metalloproteinases
15. Relation of structure to function of the tissues of the wall of blood vessels
16. Collagenase activity in the normal rat myocardium. An immunohistochemical method
17. Collagen loss in stunned myocardium
18. Regulation of collagen degradation in the rat myocardium after infarction
19. The Role of matrix metalloproteinases in heart disease
20. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure
21. Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy
22. Purification and characterization of two related but distinct metalloproteinase inhibitors secreted by bovine aortic endothelial cells
23. Cytokines in heart failure: Pathogenetic mechanisms and potential treatment
24. Matrix Metalloproteinases and Cardiovascular Disease
25. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study
26. Targeted deletion of the MMP-9 gene attenuates left ventricular enlargement after myocardial infarction
27. Matrix metalloproteinases. A review
28. Alterations of the myocardial skeletal framework in acute myocardial infarction with and without ventricular rupture
29. Molecular cloning and expression of collagenase 3, a novel human matrix metalloproteinase produced by breast carcinomas
30. N-Acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: New target for antioxidant therapy
31. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions
32. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
33. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein
34. The role of monocyte in atherogenesis. I Transition of bloodborne monocytes into foam cells in fatty lesions
35. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs
36. Treating periodontal diseases by blocking tissue-destructive enzymes
37. Collagenolytic activity in amphibian tissues: A tissue culture assay
38. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links
39. The collagen substrate specifity of human neutrophil collagenase
40. Medial neovascularization in abdominal aortic aneurysms: A histopathologic marker of aneurysm degeneration with pathophysiologic implications
41. The role of cytokines in the failing human heart
42. Processing a precursor of 72-kilodalton type IV collagenase/gelatinase. A by a recombinant-membrane-type 1 matrix metalloproteinase
43. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis
44. Biochemical characterization of human collagenase-3
45. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: Association of MMP induction with bone resorption
46. Angiotensin II receptor blockade during gestation attenuates collagen formation in the developing rat heart
47. Minocycline in rheumatoid arthritis
48. Dynamic state of collagen: Pathways of collagen degradation in vivo and their possible role in regulation of collagen mass
49. Differential responses of adult cardiac fibroblasts to in vitro biaxial strain patterns
50. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture
51. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart
52. Pathogenesis of abdominal aortic aneurysm
53. Autoreactivity to the cardiac myocyte, connective tissue and the extracellular matrix in heart disease and postcardiac injury
54. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: A quantitative assessment
55. Size matters. The relationship between MMP-9 expression and aortic diameter
56. Characterisation of left ventricular collagen in the rat
57. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1)
58. Collagen polymorphism in the normal and diseased blood vessel wall: Investigation of collagen types I, III and V
59. Collagen types in various layers of the human aorta and their changes with the atherosclerotic process
60. Matrix metalloproteinases in abdominal aortic aneurysm: Characterization, purification, and their possible sources
61. Macrophages contain 92-kD gelatinase (MMP-9) at the site of degenerated internal elastica lamina in temporal arteriitis
62. Differential myocardial abundance of collagen type I and type III mRNA in dilated cadriomyopathy: Effects of myocardial inflammation
63. Suppression of experimental aneurysmal degeneration with chemically modified tetracycline derivatives
64. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: Preservation of aortic elastin associated with suppressed production of 92 kD gelatinase
65. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
66. Genetic variants of collagen III and abdominal aortic aneurysm
67. Genetic variation on chromosome 16 is associated with abdominal aortic aneurysm
68. Multifactorial inheritance of abdominal aortic aneurysm
69. Smoking as a risk factor for abdominal aortic aneurysm
70. Molecular cloning of a novel membrane-type matrix metalloproteinase from human breast carcinoma
71. Are aortic aneurysms caused by atherosclerosis?
72. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice
73. The pathogenesis of atherosclerosis: An update
74. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
75. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis
76. A matrix metalloproteinase expressed on the surface of tumour cells
77. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy
78. Relative distribution of fibronectin and type I, III, IV, V collagens in normal and atherosclerotic intima of human arteries
79. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
80. The influence of age and atherosclerosis on the chemsitry of aortic intima
81. Procollagenase is reduced to inactive fragments upon activation in the presence of doxycycline
82. Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function
83. Multiple methods of activation of latent fibroblast collagenase: Evidence for the role of Cys73 active-site zinc complex in latency and a 'cystein-switch' mechanism for activation
84. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)
85. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family
86. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques
87. Collagen degradation in ischemic rat heart
88. Involvement of protein kinase C in the interleukin 1 alpha-induced gene expression of matrix metalloproteinases and tissue inhibitor-1 of metalloproteinases (TIMP-1) in human uterine cervical fibroblasts
89. Identification of the second membrane-type matrix metalloproteinase (MT-MMP2) gene from a human placenta cDNA library. MT-MMPs from a unique membrane-type subclass in the MMP family
90. Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate
91. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension
92. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
93. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy
94. Fibronectin fragments, but not intact fibronectin, signalling through the fibronectin receptor induce metalloproteinase gene expression in fibroblasts
95. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes
96. Metalloproteinases in degenerative aortic disease
97. Cardiac intersitium: Extracellular space of the myocardium
98. Monitoring tissue repair and fibrosis from a distance
99. Structural remodeling of the infarcted rat heart
100. Wound healing following myocardial infarction
101. Collagen network of the myocardium: Function, structural remodeling and regulatory mechanisms
102. Neutral metalloproteinases produced by human mononuclear phagocytes: Enzyme profile, regulation and cellular differentiation
103. The collagen substrate specifity of human skin fibroblast collagenase
104. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment
105. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP)
106. Matrix Metalloproteinases and their inhibitors in connective tissue remodeling
107. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages
108. Collagen in dilated cardiomyopathy: Scanning electron microscopic and immunohistochemical observations
109. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure